| Title: |
Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study |
| Authors: |
Beyar Katz, Ofrat; Perry, Chava; Grisariu‐Greenzaid, Sigal; Yehudai‐Ofir, Dana; Luttwak, Efrat; Avni, Batia; Zuckerman, Tsila; Sdayoor, Inbal; Stepensky, Polina; Ringelstein‐Harlev, Shimrit; Bar‐On, Yael; Libster, Diana; Sharvit, Liat; Amit, Odelia; Greenbaum, Uri; Gold, Ronit; Herishanu, Yair; Benyamini, Noam; Avivi, Irit; Ram, Ron |
| Source: |
European Journal of Haematology ; volume 111, issue 1, page 63-71 ; ISSN 0902-4441 1600-0609 |
| Publisher Information: |
Wiley |
| Publication Year: |
2023 |
| Collection: |
Wiley Online Library (Open Access Articles via Crossref) |
| Description: |
Chimeric antigen receptor T‐cells (CAR‐T) are widely used for the treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL). The data for CAR‐T cell therapy in patients with extra‐nodal (EN) lymphoma is restricted. We included 126 consecutive patients with DLBCL treated with commercially available CAR‐T cells (tisagenlecleucel, n = 100, 79.4% and axicabtagene ciloleucel, n = 26, 20.6%). At lymphodepletion, 72 of 126 (57%) patients had EN disease, 42 of 126 (33%) patients had nodal disease (ND)‐only and 12 of 126 (10%) showed no disease assessed by PET‐CT. There were no significant differences in CAR‐T related toxicities and in the median Progression free survival (PFS) between EN patients and ND (10.76 [95% CI: 7.8–13.6] vs. 14.1 [95% CI: 10–18.1] months, p = .126). Similarly, median overall survival (OS) was not significantly different (15.36 [95% CI 12.5–18.2] vs. 18.4 [95% CI 14.8–22.1] months, p = .100). Subgroup analysis according to the number of EN involved sites showed that median PFS and OS were significantly higher in patients with 2 EN sites, respectively (16.5 months [95% CI 13.4–19.6] vs. 8.7 months [95% CI 4.6–12.8], p = .05). In multivariate cox regression analysis, increased number sites of EN disease and high lactate dehydrogenase (LDH) at lymphodepletion negatively impacted PFS ( p = .021 and 2 EN sites at lymphodepletion have significantly worse clinical outcomes compared to patients with |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| DOI: |
10.1111/ejh.13968 |
| Availability: |
https://doi.org/10.1111/ejh.13968; https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13968 |
| Rights: |
http://onlinelibrary.wiley.com/termsAndConditions#vor |
| Accession Number: |
edsbas.9ACD71BF |
| Database: |
BASE |